SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a pharmaceutical company specializing in central nervous system therapies, has announced an international patent application through its collaboration with Clearmind Medicine Inc. The patent is for a novel composition aimed at preventing and treating depression, leveraging a compound from SciSparc’s CannAmide™ and Clearmind’s MEAI. This move comes amidst a growing depression and anxiety treatment market, projected to more than double by 2034.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
